NEWARK, Calif., June 8, 2026
Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its investigational TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association (PHA) Conference in Dallas, Texas. The once-daily transdermal patch is being developed for the treatment of pulmonary arterial hypertension (PAH) and is designed to provide continuous systemic exposure to treprostinil through a novel prodrug delivery approach. The company reported encouraging pharmacokinetic, tolerability, and dosing results from healthy volunteer studies, supporting continued clinical development of the therapy.
Phase 1 Results Support Continued Development
The Phase 1 data demonstrated that TRX-248 delivered steady and continuous exposure to treprostinil, a widely used prostacyclin therapy for PAH. Unlike existing administration methods, the investigational patch delivers an inactive prodrug that passes through the skin and is converted into active treprostinil in the liver. This approach is intended to simplify treatment administration while maintaining therapeutic drug exposure. The findings suggest the technology could potentially address challenges associated with current prostacyclin delivery methods and improve treatment convenience for patients living with PAH.
Innovative Transdermal Approach for PAH Treatment
Pulmonary arterial hypertension is a progressive and life-threatening disease that significantly impacts breathing capacity and quality of life. Although prostacyclin therapies remain a cornerstone of treatment, many patients face difficulties with current administration options. Corsair’s TRX-248 Transdermal System aims to provide a non-invasive, once-daily alternative that may improve treatment adherence and patient experience. The company also believes the technology may have broader potential across other forms of pulmonary hypertension, expanding its future therapeutic applications.
Advertisement
Multiple Presentations Highlight Clinical Findings
At the PHA 2026 Conference, Corsair’s clinical data will be featured through multiple scientific presentations. The company’s poster presentation will detail pharmacokinetic and safety findings from the Phase 1 study, while additional sessions will discuss the clinical implications of the transdermal delivery platform and its potential role in future PAH management. Experts presenting the data will highlight how the investigational patch may offer continuous treprostinil exposure with modest skin irritation, supporting its development as a patient-friendly treatment alternative.
Growing Opportunity in the PAH Market
The market for prostacyclin therapies in PAH remains substantial, with annual U.S. sales estimated at approximately $3.3 billion. Despite advances in treatment, significant unmet medical needs remain, particularly among patients unable or unwilling to use current prostanoid therapies. By leveraging a streamlined regulatory pathway and a differentiated transdermal technology platform, Corsair Pharma aims to bring a potentially transformative treatment option to the PAH community. The positive Phase 1 findings represent an important milestone as the company advances TRX-248 toward future clinical development stages.
Source: Corsair Pharma, press release
